Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy

Journal of Clinical Virology

Volumn 51, Issue 3, 2011, Pages 195-198

  Gaillard, Stephanie ^a   Dinoso, Jason B ^a   Marsh, Julia A ^a   DeZern, Amy E ^a   O'Connell, Karen A ^a   Spivak, Adam M ^a   Alwood, Karla ^a   Durand, Christine M ^a   Ambinder, Richard F ^a   Blankson, Joel N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Elite controllers; Elite suppressors; HIV; Neutralizing antibody; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS REPLICATION; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG THERAPY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 79959258987     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.04.002     Document Type: Article

References (19)

1. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
2. Blankson J.N., Bailey J.R., Thayil S., Yang H.C., Lassen K., Lai J., et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007, 81:2508-2518.
3. Bailey J.R., O'Connell K., Yang H.C., Han Y., Xu J., Jilek B., et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 2008, 82:7395-7410.
4. Aksoy S., Harputluoglu H., Kilickap S., Dede D.S., Dizdar O., Altundag K., et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007, 48:1307-1312.
5. Huang K.H., Bonsall D., Katzourakis A., Thomson E.C., Fidler S.J., Main J., et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun 2010, 1:102.
6. Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411.
7. Ramratnam B., Bonhoeffer S., Binley J., Hurley A., Zhang L., Mittler J.E., et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354:1782-1785.
8. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
9. Bailey J.R., Lassen K.G., Yang H.C., Quinn T.C., Ray S.C., Blankson J.N., et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006, 80:4758-4770.
10. Pereyra F., Addo M.M., Kaufmann D.E., Liu Y., Miura T., Rathod A., et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008, 197:563-571.
11. Doria-Rose N.A., Klein R.M., Manion M.M., O'Dell S., Phogat A., Chakrabarti B., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009, 83:188-199.
12. Puissant-Lubrano B., Rostaing L., Kamar N., Abbal M., Fort M., Blancher A. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients. Exp Clin Transplant 2010, 8:19-28.
13. O'Connell K.A., Brennan T.P., Bailey J.R., Ray S.C., Siliciano R.F., Blankson J.N. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 2010, 84:7018-7028.
14. Mens H., Kearney M., Wiegand A., Shao W., Schonning K., Gerstoft J., et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010, 84:12971-12981.
15. Salgado M., Brennan T.P., O'Connell K.A., Bailey J.R., Ray S.C., Siliciano R.F., et al. Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. Retrovirology 2010, 7:94.
16. Friedrich T.C., Valentine L.E., Yant L.J., Rakasz E.G., Piaskowski S.M., Furlott J.R., et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007, 81:3465-3476.
17. Kawashima Y., Kuse N., Gatanaga H., Naruto T., Fujiwara M., Dohki S., et al. Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101. J Virol 2010, 84:7151-7160.
18. Rabi S.A., O'Connell K.A., Nikolaeva D., Bailey J.R., Jilek B.L., Shen L., et al. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol 2011, 85:979-986.
19. Graf E.H., Mexas A.M., Yu J.J., Shaheen F., Liszewski M.K., Di Mascio M., et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011, 7:e1001300.